$TRON Quick thoughts on BOD integration: "Our t
Post# of 178
"Our transition team is poised to add efficiencies to the operations of The InMed Group to strengthen and grow cash flow. Moreover, we are negotiating with several financial institutions to provide Toron with a substantial operating line of credit to further add efficiencies for InMed operations and facilitate Toron's continued growth," further added Ortiz Morentin.
(*Note: Finances from paragraph above were later granted: https://backend.otcmarkets.com/otcapi/company...29/content )
We are pleased to announce that Brad Eisemann, InMed's Chief Operating Officer, will be joining the Toron Board of Directors along with Rene Ortiz Morentin and Patrick Ryan. Mr. Eisemann has been with InMed for the past 15 years and has been key in developing and implementing new strategic revenue sources, creating sustainable change within healthcare facilities; enhancing medical management practices, and creating, evaluating and implementing strategically sound M&A opportunities. Mr. Eisemann has more than 10 years of experience as a Chief Executive Officer of healthcare facilities including hospitals and assisted living facilities. Mr. Eisemann served over 20 years in the U.S. Air Force and retired with honors as a Master Sergeant. Mr. Eisemann holds Bachelor of Science in Finance from Hawaii Pacific University in Honolulu, Hawaii.
"We will be finalizing our new board members in late November," stated Ortiz Morentin.
Source: https://www.otcmarkets.com/stock/TRON/news/To...?id=207913
Specific attention paid to the last line, no formal announcement of completion of BOD integration/finalization was promised; possibly stating that was the announcement. A more formal sounding of the horn may come either via updating NVSOS and/or details in the 8k soon to come(quoted just below from the CEO on the Toron website forum - see: "Management Response" :
"It is Toron’s intent to become a fully reporting company. We are currently finalizing our choice of auditors who will have no small task ahead of them, auditing Toron and its subsidiaries, iMedScan and The InMed Group. We will be instilling a stronger corporate vision internally. With this vision in mind, we have decided to file an 8K and should be doing so in short order."
There may be any number of reasons for the delay, or the choice not to announce further at this time. It seems to me, and to each their own, that more weight should be held in the confirmations of financing by Mr. Shah and Mr. Jarry(respectively), as well as the back history of undisputed press releases of the InMed deal, culminating the InMed CEO(again, Mr. Jarry) publicly announcing the finalization of InMed as a member of the Toron family, as depicted in the most recent PR(linked just below):
https://backend.otcmarkets.com/otcapi/company...18/content
Alternatively, prior to the 8k, or shortly thereafter, depending on the amount of detail going into it, and the desired timing of its release, a PR or back end update could come out in close proximity of the Dec 21st date of estimation mentioned in the shareholder briefing linked just prior to this paragraph.
And while the BOD info is great, as are the individual players that comprise it, my thoughts are not to sweat the small stuff when the big stuff is in line. If a delay on this is enough to crash a stock, there is little faith in the substance of a company; yet if the price can remain relatively stable, with swings accounted for, then the long term holders have favorable sentiment regarding the backbone of the company and its future.
Capping off, if management is savvy enough to lock in a major deal such as InMed, not to mention a 30yr track record of some pretty incredible M & A deals, then I see no reason not to trust how they wish to roll out public information. The CEO is not focused on the share price, but instead on the company's core value. Increase the core value and the price will follow. If the price drops, it will catch up to its book value, which is the core of the company - and any investor who sees an 8k or future financials showing a stock trading well below book value, sees an undervalued asset worth picking up, especially since Toron has had a low float of 299M for 2yrs, and does not promote the stock for the sake of selling shares into the 299M.
Everything will catch up. The 8k and the finalization of state and federal paperwork, both listing the deal as closed, and the recently acquired InMed as a then current and future subsidiary of Tororn, are what's really important.
My current curiosity is on the what will be acquired and/or added to Toron and its subsidiaries with the approval of the second $10M, seeing as the first $10.9M yielded the acquisition of 3 hospitals and 10 assisted living facilities in 8 separate locations.